ShigETEC vaccine candidate against diarrhoeal disease proved to be safe in phase I clinical trial
Diarrhoea is one of the most common diseases, globally, affecting children under five years of age. Although typically being a...
top of page
Search
EVI
- Sep 24, 2020
Eveliqure announces the start of a Phase 1 clinical study of its combined Shigella and ETEC vaccine
ShigETEC is an orally administered vaccine candidate developed by Eveliqure.
EVI
- Nov 5, 2019
Eveliqure's effort to develop a Shigella-ETEC combination vaccine is supported by the Wellcome Trust
Shigella-ETEC combination vaccine for travellers and children in resource poor countries is supported by the Wellcome Trust.
EVI
- Oct 25, 2019
“Success Story” series of the Austrian Research Promotion Agency (FFG)
The SHIGETECVAX consortium and Eveliqure included in the “Success Story” series of the Austrian Research Promotion Agency (FFG)
EVI
- Oct 15, 2019
SHIGETECVAX Kick-off meeting
The official kick-off meeting of the SHIGETECVAX project was held at the Eveliqure facilities in Vienna, Austria.
EVI
- Sep 12, 2019
Early clinical development of a live, attenuated combination vaccine against Shigella and ETEC
SHIGETECVAX included in the Community Research and Development Information Service (CORDIS).
EVI
- Sep 10, 2019
International partnership to advance the development of a new vaccine against Shigella and ETEC
Horizon2020 award to consortium will support the testing of an innovative live attenuated vaccine in phase I clinical trials.
bottom of page